Northern Trust Corp Cardiff Oncology, Inc. Transaction History

Northern Trust Corp

$658 Billion
Q1 2025

A detailed history of Northern Trust Corp transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 484,364 shares of CRDF stock, worth $1.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

484,364

Previous 337,092 43.69%

Holding current value

$1.55 Million

Previous $1.46 Million 3.97%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$3.14 - $4.75 $462,434 - $699,542	147,272 Added 43.69%	484,364 $1.52 Million
Q4 2024 Feb 14, 2025	BUY	$2.31 - $5.35 $63,499 - $147,066	27,489 Added 8.88%	337,092 $1.46 Million
Q3 2024 Nov 13, 2024	BUY	$2.05 - $2.77 $432,877 - $584,913	211,160 Added 214.5%	309,603 $826,000
Q2 2024 Aug 14, 2024	BUY	$2.22 - $5.89 $28,704 - $76,157	12,930 Added 15.12%	98,443 $218,000
Q1 2024 May 14, 2024	BUY	$1.46 - $5.91 $20,625 - $83,490	14,127 Added 19.79%	85,513 $456,000
Q3 2023 Nov 13, 2023	SELL	$1.38 - $2.18 $1,380 - $2,180	-1,000 Reduced 1.38%	71,386 $99,000
Q2 2023 Aug 11, 2023	BUY	$1.37 - $1.95 $2,689 - $3,827	1,963 Added 2.79%	72,386 $106,000
Q1 2023 May 15, 2023	BUY	$1.45 - $2.09 $1,506 - $2,171	1,039 Added 1.5%	70,423 $116,000
Q3 2022 Nov 14, 2022	BUY	$1.54 - $3.21 $4,299 - $8,962	2,792 Added 4.19%	69,384 $107,000
Q2 2022 Aug 12, 2022	SELL	$1.17 - $2.61 $293,981 - $655,804	-251,266 Reduced 79.05%	66,592 $147,000
Q1 2022 May 13, 2022	SELL	$2.11 - $7.25 $44,780 - $153,866	-21,223 Reduced 6.26%	317,858 $788,000
Q4 2021 Feb 08, 2022	BUY	$5.18 - $7.24 $79,642 - $111,315	15,375 Added 4.75%	339,081 $2.04 Million
Q3 2021 Nov 15, 2021	BUY	$5.01 - $7.58 $29,363 - $44,426	5,861 Added 1.84%	323,706 $2.16 Million
Q2 2021 Aug 13, 2021	BUY	$6.65 - $10.04 $1.8 Million - $2.72 Million	271,248 Added 582.11%	317,845 $2.11 Million
Q1 2021 May 12, 2021	BUY	$9.1 - $19.57 $18,900 - $40,646	2,077 Added 4.67%	46,597 $431,000
Q4 2020 Feb 11, 2021	BUY	$12.02 - $24.71 $236,830 - $486,861	19,703 Added 79.39%	44,520 $801,000
Q3 2020 Nov 16, 2020	BUY	$4.25 - $14.19 $57,268 - $191,210	13,475 Added 118.81%	24,817 $352,000
Q2 2020 Aug 14, 2020	BUY	$0.78 - $5.1 $8,846 - $57,844	11,342 New	11,342 $57,000

Others Institutions Holding CRDF

# of Institutions

124

Shares Held

29M

Call Options Held

900K

Put Options Held

234K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $139M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Cardiff Oncology, Inc. Transaction History